<DOC>
	<DOCNO>NCT02263885</DOCNO>
	<brief_summary>The propose study evaluate safety , initial efficacy use ExAblate Transcranial create unilateral lesion globus pallidus adjunct PD medication subject 30 year age consider medication-refractory advanced idiopathic Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>ExAblate Transcranial MRgFUS Globus Pallidum Treatment Parkinson 's Disease</brief_title>
	<detailed_description>The purpose study evaluate safety initial clinical effectiveness ExAblate Transcranial unilateral thermal ablation globus pallidus subject suffer medication-refractory , advance idiopathic PD . Data collect establish basic safety clinical efficacy type treatment basis later study evaluate full clinical efficacy .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Men woman , age 30 year old Subjects able willing give inform consent able attend study visit 24 Months Subjects diagnosis idiopathic PD Levodopa responsive define least 30 % reduction MDSUPDRS motor subscale ON v OFF medication state . Disabling motor complication PD optimum medical treatment Predominant disability one side body ( i.e unilateral markedly asymmetric disease ) determine movement disorder neurologist neurosurgeon Subjects stable dose PD medication 30 day prior study entry . Subject able communicate sensation ExAblate Transcranial procedure . Presence central neurodegenerative disease suspect neurological examination . These include : multisystem atrophy , progressive supranuclear palsy , corticobasal syndrome , dementia Lewy body , Alzheimer 's disease . Any suspicion Parkinsonian symptom side effect neuroleptic medication . Subjects deep brain stimulation prior stereotactic ablation basal ganglia Unstable psychiatric disease , define active uncontrolled depressive symptom , psychosis , delusion , hallucination , suicidal ideation . Subjects stable , chronic anxiety depressive disorder may include provided medication stable least 60 day prior study entry deem appropriately manage site neuropsychologist Subjects significant depression determine follow comprehensive assessment neuropsychologist . Legal incapacity limit legal capacity determine neuropsychologist Subjects exhibit behavior ( ) consistent ethanol substance abuse Subjects unstable cardiac status include : 1 . Unstable angina pectoris medication 2 . Subjects document myocardial infarction within six month protocol entry 3 . Significant congestive heart failure define ejection fraction &lt; 40 4 . Subjects unstable ventricular arrhythmia 5 . Subjects atrial arrhythmia ratecontrolled Severe hypertension ( diastolic BP &gt; 100 medication ) Current medical condition result abnormal bleeding and/or coagulopathy Receiving anticoagulant ( e.g . warfarin ) antiplatelet ( e.g . aspirin ) therapy within one week focus ultrasound procedure drug know increase risk hemorrhage ( e.g . Avastin ) within one month focus ultrasound procedure Subjects risk factor intraoperative postoperative bleeding indicate : platelet count le 100,000 per cubic millimeter , document clinical coagulopathy , INR coagulation study exceed institution 's laboratory standard Patient severely impair renal function estimate glomerular filtration rate &lt; 30 mL/min/1.73m2 ( per local standard restrictive ) and/or dialysis ; Subjects standard contraindication MR image nonMRI compatible implant metallic device include cardiac pacemaker , size limitation , etc . Significant claustrophobia manage mild medication . Subjects able willing tolerate require prolonged stationary supine position treatment . History intracranial hemorrhage History multiple stroke , stroke within past 6 month Subjects history seizure within past year Subjects brain tumor Subjects intracranial aneurysm require treatment arterial venous malformation ( AVMs ) require treatment . Are participate participate another clinical trial last 30 day Any illness investigator 's opinion preclude participation study . Subjects unable communicate investigator staff . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>ExAblate</keyword>
	<keyword>MRgFUS</keyword>
</DOC>